Medical Device FDA 510(k) Clearance
Clearance is the moment a medical device stops being a research program and becomes a product that has to be manufactured at volume, tracked through a regulated quality system, sold into hospital procurement, and supported in the field. Almost everything the company needs to do that, it does not yet have. The FDA publishes every clearance with the applicant, the device, and the date, which makes this one of the most precisely timed buying signals available in life sciences. Avina detects clearance and the commercialization buildout that follows it.
Why FDA Clearance Is a Buying Signal for Sales Teams
The gap between a cleared device and a commercially available one is where the spending happens. Clearance obligates the company to operate a quality management system under 21 CFR Part 820 and, increasingly, ISO 13485 — with document control, design history files, complaint handling, CAPA, supplier qualification, and audit readiness. Companies that made it through submission on spreadsheets and shared drives cannot survive an FDA inspection that way, and an electronic quality management system is typically the first purchase after clearance. Manufacturing scale-up follows immediately. Producing a device for a submission is not the same as producing it repeatably under validated processes with lot traceability and unique device identification. That means manufacturing execution and traceability systems, supplier quality management, sterilization and packaging validation, and in many cases a contract manufacturer relationship that itself has to be qualified and audited. Post-market obligations begin the day the device is sold. Complaint intake, medical device reporting, field action and recall capability, and post-market surveillance are legal requirements with defined timelines, and they cannot be run informally. Companies discover this when the first complaint arrives and there is no system to log it in. Then there is commercialization itself, which is a full go-to-market buildout compressed into a few quarters. Hospital sales require contracting through group purchasing organizations and integrated delivery networks, credentialing for reps entering clinical settings, reimbursement and coding strategy so the buyer can get paid, field service and inventory management for consigned devices, and a CRM configured for a sales motion that runs through committees rather than individuals. A newly cleared company is buying most of that for the first time, with investor money raised specifically to do it.
How Does Avina Detect FDA Clearances?
The FDA publishes 510(k) and De Novo decisions with the applicant name, device name, product code, decision date, and the predicate device where applicable. Avina monitors these releases and resolves the applicant to a company record, which makes the trigger exact — there is no inference about whether the event happened or when. Product codes and device classes are retained, because a Class II diagnostic and an implantable device imply very different obligations and very different buyers. Establishment registration and device listing records add the manufacturing picture, including whether the company manufactures itself or relies on a contract manufacturer, and whether new facilities have been registered. First-time registrants are separated from established manufacturers adding a device, since a company clearing its first product is buying an entire operating infrastructure while an established one is extending systems it already has. Hiring identifies which phase the company is in and where the gaps are. Listings for quality engineers, regulatory affairs specialists, complaint handling and post-market surveillance roles, manufacturing and process engineers, and — the clearest commercialization marker — the first field sales, clinical specialist, market access, and reimbursement hires. Press releases, investor announcements, and financing disclosures corroborate the commercial timeline and reveal how much capital is behind the launch. Clinical and health economics publications indicate a reimbursement strategy taking shape, which usually precedes the sales buildout by a quarter.
What Happens When a Clearance Signal Fires?
Avina scores the account on device class and product code, whether this is a first clearance or an addition to an existing portfolio, manufacturing model, corroborating quality and commercial hiring, and recent financing. A first-time applicant with fresh capital, open quality roles, and its first field sales listing is a materially better opportunity than an established manufacturer clearing a line extension. Relevant contacts — VP of Quality, Head of Regulatory Affairs, VP of Operations or Manufacturing, Chief Commercial Officer, and Head of Market Access — are enriched with verified emails, phone numbers, and LinkedIn profiles through waterfall enrichment. Reps receive a Slack alert with the clearance record, the device and product code, the manufacturing registration status, and the corroborating hiring. Salesforce or HubSpot records are updated with the clearance date so account owners can work the commercialization timeline rather than a single announcement. Qualified accounts can be auto-enrolled into Outreach or Salesloft sequences matched to phase — quality management and document control immediately after clearance, manufacturing and traceability during scale-up, post-market and complaint handling before first sale, and commercial systems as the field team is hired.
Start Tracking FDA Clearances With Avina
Clearance starts a funded, deadline-bound buildout of quality, manufacturing, and commercial infrastructure. Activate this signal in Avina's Signals Library to reach these companies in the quarter it happens. Every plan includes a 7-day free trial with no credit card required.